There is evidence that KRAS mutations are highly specific negative prognostic factors of response (de novo resistance) to EGFR-targeted therapy in both NSCLC and colorectal cancer (Bokemeyer et al, 2009; Jackman et al, 2009). The gene discussed is KRAS; the disease is colorectal cancer.